Genprex, Inc. (GNPX), a clinical-stage gene therapy company focused on cancer and diabetes, announced Wednesday the expansion of multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Therapy in combination with Genentech's Tecentriq to treat extensive-stage small cell lung cancer or ES-SCLC.
In pre-market activity on the Nasdaq, Genprex shares were gaining around 7.7 percent to trade at $3.06.
Through its collaboration agreement with a large network of integrated, community-based oncology practices, the company said it has added multiple clinical trial sites for the trial.
ES-SCLC is an aggressive form of lung cancer that is presently incurable. ES-SCLC has a median progression free survival or PFS of 5.4 months from the start of initial therapy. However, once patients start receiving maintenance therapy with Tecentriq they have a median PFS of only 2.6 months.
It is expected that the combination of REQORSA and Tecentriq as maintenance therapy may provide a new therapeutic option for the treatment of small cell lung cancer.
Genprex has received U.S. Food and Drug Administration Ophran Drug and Fast Track designations for the Acclaim-3 patient population.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.